Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 × anti-CD3 bispecific diabody

Cancer Letters

Volumn 177, Issue 1, 2002, Pages 29-39

  Xiong, Dongsheng ^a   Xu, Yuanfu ^a   Liu, Hanzhi ^a   Peng, Hui ^a   Shao, Xiaofeng ^a   Lai, Zenzu ^a   Fan, Dongmei ^a   Yang, Min ^a   Han, Junling ^a   Xie, Yong ^b   Yang, Chunzheng ^a   Zhu, Zhenping ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

Anti CD20; Anti CD3; B cell lymphoma; Bispecific antibody; Cancer therapy; Diabody

Indexed keywords

BISPECIFIC ANTIBODY; HI 47; HIT 3 A; IMMUNOGLOBULIN G3; MONOCLONAL ANTIBODY CD3;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER INHIBITION; CANCER SURVIVAL; CELL STRUCTURE; CONTROLLED STUDY; CROSS LINKING; CYTOLYSIS; ESCHERICHIA COLI; FEMALE; GENE CONSTRUCT; GENETIC CODE; HUMAN; HUMAN CELL; INOCULATION; LYMPHOMA CELL; MOUSE; NONHUMAN; NUDE MOUSE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; T LYMPHOCYTE; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD20; ANTIGENS, CD3; BINDING SITES, ANTIBODY; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; GENETIC VECTORS; HUMANS; JURKAT CELLS; LYMPHOMA, B-CELL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RECOMBINANT PROTEINS; SURVIVAL RATE; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA; ESCHERICHIA COLI; MUS MUSCULUS;

EID: 0037040433     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(01)00758-3     Document Type: Article

References (43)

1. Clinical perspectives of bispecific antibodies in cancer
2. Bispecific antibodies in cancer therapy
3. Immunotherapeutic perspective for bispecific antibodies
4. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells
5. HER2 overexpressing tumor cells
6. Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins
7. Clinical experience with CD64-directed immunotherapy. An overview
8. A bispecific diabody that mediates natural killer cell cytotoxicity against xenografted human Hodgkin's tumors
9. Therapeutic efficacy of FcγRI/CD64-directed bispecific antibodies in B-cell lymphoma
10. High level secretion of a humanized bispecific diabody from Escherichia coli
11. Bispecific CD3 × CD19 diabody for T cell-mediated lysis of malignant B cells
12. A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes
13. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 × CD19 tandem diabody, and CD28 costimulation
14. Treatment of human B cell lymphoma xenografts with a CD3 × CD19 diabody and T cells
15. Preliminary trial of specific targeting therapy against malignant glioma
16. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2
17. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody
18. Clinical experience with CD3 × CD19 bispecific antibodies in patients with B cell malignancies
19. Toward the production of bispecific antibody fragments for clinical applications
20. New protein engineering approaches to multivalent and bispecific antibody fragments
21. 'Diabodies': Small bivalent and bispecific antibody fragments
22. Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody
23. Characterization of a human B lymphocyte specific antigen
24. CD20: A regulator of cell cycle progression of B lymphocytes
25. Rituximab: A new monoclonal antibody therapy for non-Hodgkin's lymphoma
26. Antibody-targeted therapy for low-grade lymphoma
27. Radiolabeled antibody therapy of B-cell lymphomas
28. 90Y-labeled anti-CD20 monoclonal antibody
29. Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: The Seattle experience
30. Isolation, characterization and biological activity of a monoclonal antibody directed against human mature B lymphocytes
31. Production and characterization of HIT3a, a monoclonal antibody directed against human CD3
32. Rodent to human antibodies by CDR grafting
33. Nucleotide sequence of the gene for heat-stable enterotoxin II of Escherichia coli
34. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library
35. Inhibition of human B-cell chronic lymphocytic leukemia by a monoclonal antibody in xenograft models
36. Nonparametric estimations from incomplete organizations
37. Clinical trials of antibody therapy
38. Monoclonal antibody therapy for solid tumors
39. Monoclonal antibody therapy of cancer
40. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms
41. Triggering Fc-alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy
42. Pharmacokinetics, biodistribution, and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab′)2 in ovarian carcinoma patients